<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423500</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2005-005106-23</org_study_id>
    <nct_id>NCT01423500</nct_id>
  </id_info>
  <brief_title>ALL-SCT BFM International- HSCT in Children and Adolescents With ALL</brief_title>
  <acronym>ALL-SCT-BFMi</acronym>
  <official_title>Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anna Kinderkrebsforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Anna Kinderkrebsforschung</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this protocol the ALL-SCT BFM international study group wants

        -  to evaluate whether hematopoietic stem cell transplantation (HSCT) from matched family
           or unrelated donors (MD) is equivalent to the HSCT from matched sibling donors (MSD).

        -  to evaluate the efficacy of hematopoietic stem cell transplantation (HSCT)from
           mismatched family or unrelated donors (MMD) as compared to HSCT from matched sibling
           donors or matched donors.

        -  to determine whether therapy has been carried out according to the main HSCT protocol
           recommendations. The standardisation of the treatment options during HSCT from different
           donor types aims at the achievement of an optimal comparison of survival after HSCT with
           survival after chemotherapy only.

        -  to prospectively evaluate and compare the incidence of acute and chronic
           Graft-versus-Host-Disease (GvHD) after HSCT from matched sibling donor (MSD), from
           matched donor (MD) and from mismatched donor (MMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with high risk or relapsed acute lymphoblastic leukaemia (ALL) have a worse
      prognosis compared to all other patients with ALL. For these patients additional therapy
      approaches are required after they have achieved remission with multimodal chemotherapy.
      Allogeneic haematopoetic stem cell transplantation shows promising results mainly due to an
      immunological antileukaemic control by the graft-versus-leukaemia effect but treatment
      related mortality and morbidity remains a serious problem.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>10 years</time_frame>
    <description>Event-free and overall survival after allogeneic HSCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with GvHD acute and chronic Graft-versus-Host-Disease (GvHD)</measure>
    <time_frame>10 years</time_frame>
    <description>evaluation of the incidence and severity of acute Grade I-IV graft versus Host disease and of limited or extensive chronic graft versus host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and course of late effects after chemotherapy with subsequent allogeneic HSCT</measure>
    <time_frame>10 years</time_frame>
    <description>evaluation of organ dysfunctions according to WHO Toxicity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and course of late effects after chemotherapy with subsequent allogeneic HSCT</measure>
    <time_frame>10 years</time_frame>
    <description>evaluation of growth retardation and endocrine dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and course of late effects after chemotherapy with subsequent allogeneic HSCT</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluation of incidence of aseptic bone necrosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence and course of subsequent malignancies after chemotherapy with subsequent allogeneic HSCT</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluation of incidence of secondary cancer after total body irradiation and/or chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Lymphoblastic Leukemia, Acute, Childhood;</condition>
  <arm_group>
    <arm_group_label>MSD - Matched Sibling Donor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with a MSD receive a conditioning of TBI (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD - Matched Donor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMD - Mismatched Donor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with a MMD receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16</intervention_name>
    <description>patients with MSD receive as conditioning VP16 60mg/kg/d on day -3</description>
    <arm_group_label>MSD - Matched Sibling Donor</arm_group_label>
    <other_name>Etoposid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning</description>
    <arm_group_label>MSD - Matched Sibling Donor</arm_group_label>
    <other_name>Total body irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16, ATG</intervention_name>
    <description>patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1</description>
    <arm_group_label>MD - Matched Donor</arm_group_label>
    <other_name>Etoposid, Antithymoglobuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)</description>
    <arm_group_label>MD - Matched Donor</arm_group_label>
    <other_name>total body irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, OKT3, Treosulfan, Thiotepa</intervention_name>
    <description>patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4</description>
    <arm_group_label>MMD - Mismatched Donor</arm_group_label>
    <other_name>ATG: Antithymoglobuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16, ATG</intervention_name>
    <description>patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d</description>
    <arm_group_label>MMD - Mismatched Donor</arm_group_label>
    <other_name>VP16: Etoposid</other_name>
    <other_name>ATG: Antithymoglobuline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions</description>
    <arm_group_label>MMD - Mismatched Donor</arm_group_label>
    <other_name>TBI: total body irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age at time of initial diagnosis or relapse diagnosis, respectively under or equal 18
             years

          -  indication for allogeneic hematopoietic stem cell transplantation(HSCT)

          -  complete remission before hematopoietic stem cell transplantation (HSCT)

          -  written consent of the parents (legal guardian) and, if necessary, the minor patient
             via Informed Consent Form

          -  no pregnancy

          -  no secondary malignancy

          -  no previous hematopoietic stem cell transplantation (HSCT)

          -  hematopoietic stem cell transplantation (HSCT) is performed in a study participating
             centre.

        Exclusion Criteria:

          -  age at time of initial diagnosis or relapse diagnosis, respectively above 18 years

          -  no indication for allogeneic HSCT

          -  no complete remission before SCT

          -  no written consent of the parents (legal guardian) and, if necessary, the minor
             patient via Informed Consent Form

          -  pregnancy

          -  secondary malignancy

          -  previous HSCT

          -  HSCT is not performed in a study participating centre.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Peters Peters, Prof MD PHD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Anna Kinderkrebsforschung</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petr Sedlacek, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Paediatric Haematology and Oncology. HSCT Unit Prague</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Ifversen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paediatric Clinic II, Rigshospitalet Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Hugues Dalle, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HSCT Unit Robert Debré Hospital Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerry Stein, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schneider Children's Medical Center, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adriana Balduzzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Gerardo Monza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Bierings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wilhelmina Children's Hospital Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacek Wachowiak, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Paediatric Oncology, Haematology and Transplantology, University of Medical Sciences Poznan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabina Sufliarska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HSCT Unit, University Children's Hospital Bratislava</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacek Toporski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Paediatric Oncology Lund</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sema Anak, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paediatric HSCT Unit, Istanbul School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akif Yesilipek, MD Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Paediatric Haematology-Oncology and HSCT, Akdeniz University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik für Kinder- und Jugendheilkunde, Klin. Abt. f. Hämato-Onkologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Children's Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Paediatric Haematology and Oncology HSCT-Unit</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Clinic II, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>4074</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Immuno-Hematology Unit Robert Debré Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75935</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children`s Medical Center of Israel</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica dell`Universita di Milano Bicocca, Hospitale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Hospital</name>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University - Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Paediatric Haematology and Oncology, Wilhelmina Children's Hospital</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Collegium Medicum UMK, Pediatric Hematology and Oncology</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Transplantation, University Children's Hospital</name>
      <address>
        <city>Cracow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children`s University Hospital - Hematology - Oncology</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediadric Oncology, Hematology and Transplantology, University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <zip>60-572</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wroclaw Medical University, Dept. of Children Hematology and Oncology</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-345</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Bone Marrow Transplantation Unit, University Childrens´ Hospital</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Oncology, Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221-85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Gülhane Military Medical Academy</name>
      <address>
        <city>Ankara</city>
        <zip>06018</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Paediatrics - BMT Unit, School of Medicine, University of Ankara</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Hematology-Oncology and Pediatric Stem Cell Transplantation, Akdeniz University School of Medicine</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Hematology, Oncology and BMT, Istanbul School of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>343990</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric BMT Centre, Ege University</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.stanna.at/content.php?p=1&amp;lang=de</url>
    <description>website St. Anna Children's Hospital</description>
  </link>
  <results_reference>
    <citation>Peters C, Schrauder A, Schrappe M, von Stackelberg A, Stary J, Yaniv I, Gadner H, Klingebiel T; BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplant. 2005 Mar;35 Suppl 1:S9-11.</citation>
    <PMID>15812540</PMID>
  </results_reference>
  <results_reference>
    <citation>Pulsipher MA, Peters C, Pui CH. High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S137-48. doi: 10.1016/j.bbmt.2010.10.005. Review.</citation>
    <PMID>21195303</PMID>
  </results_reference>
  <results_reference>
    <citation>Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora KW, Schrum J, Kremens B, Ehlert K, Albert MH, Meisel R, Matthes-Martin S, Gungor T, Holter W, Strahm B, Gruhn B, Schulz A, Woessmann W, Poetschger U, Zimmermann M, Klingebiel T. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015 Apr 10;33(11):1265-74. doi: 10.1200/JCO.2014.58.9747. Epub 2015 Mar 9.</citation>
    <PMID>25753432</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Cancer Research Institute, Austria</investigator_affiliation>
    <investigator_full_name>Prof. Christina Peters</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ALL</keyword>
  <keyword>HSCT</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

